KDR 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
This Target Evaluation Report for KDR is generated from PatSnap Life Sciences MCP data workflows, combining Target & Disease MCP biology context with Clinical Trials MCP validation and competitive signals.
For AI teams building biomedical agents, PatSnap Life Sciences MCP Servers provide structured retrieval across target biology, disease context, clinical trials, drug evidence, IP intelligence, and other R&D intelligence sources.
328 Direct drug records from Target & Disease MCP | 220 Development records in target context | 744 Disease associations captured | 6467 Clinical trial records from Clinical Trials MCP |
Explore PatSnap Life Sciences MCP Servers for AI agents
Executive View
KDR / VEGFR2 is the main endothelial signaling receptor in angiogenesis
Target & Disease MCP resolves KDR to VEGFR2, a receptor for VEGFA, VEGFC, and VEGFD. It regulates angiogenesis, vascular development, permeability, endothelial proliferation, survival, migration, differentiation, actin reorganization, nitric-oxide signaling, MAPK, AKT, PLCG1, FAK, SRC, and PI3K pathways.
Clinical validation is massive but crowded
The MCP pull shows 328 direct drug records, 220 development records, and 744 disease associations. Clinical Trials MCP returned 6,467 trial records, with many multi-target TKIs and anti-angiogenic combinations. Selective interpretation is essential.
Competition reflects multikinase anti-angiogenic regimens
Sample trials include lenvatinib, anlotinib, and fruquintinib-containing regimens. These are strong pathway-level competitive signals but should not be read as purely VEGFR2-selective programs.
IP and strategy view
KDR differentiation depends on kinase selectivity, adverse-event management, combination logic, indication choice, and potential biomarkers for anti-angiogenic sensitivity.
Clinical Validation and Competitive Landscape
Clinical Trials MCP returned 6467 registered trial records connected to KDR. The sample below is used as a directional competitive readout rather than a full regulatory review.
| Trial | Phase | Status |
|---|---|---|
| RAINBOW: intraarterial therapies plus tislelizumab plus lenvatinib in unresectable intrahepatic cholangiocarcinoma | Phase 3 | Not yet recruiting |
| Anlotinib capsule fasting bioequivalence pilot trial | Not Applicable | Not yet recruiting |
| Sac-TMT plus fruquintinib as second-line treatment in advanced gastric/GEJ adenocarcinoma | Phase 2 | Not yet recruiting |
R&D Strategy Recommendation
KDR is strategically useful when the program has better tolerability, combination rationale, or a differentiated disease segment. A generic VEGFR2 inhibitor is unlikely to stand out.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
